BUZZ-Citigroup starts coverage of Kymera with $52 PT

Reuters03-13

BUZZ-Citigroup starts coverage of Kymera with $52 PT

** Citigroup starts coverage of Kymera Therapeutics' KYMR.O shares with "buy/high risk" rating and $52 PT, a ~48% upside to stock's last close

** Brokerage says company's targeted protein degradation technology offers "first-in-class" approaches in the treatment of various inflammatory and immunological diseases

** Company's atopic dermatitis drug KT-621 has shown "robust preclinical data" with potential to achieve "comparable or superior efficacy" to Regeneron REGN.O and Sanofi's SASY.PA Dupixent, Citigroup says

** Kymera's inflammatory skin disease drug KT-474 has shown promising data in clinical trials, particularly in hidradenitis suppurativa, where it demonstrated a "remarkable ~60% reduction in symptoms", positioning it as a potential "best-in-class" therapy - brokerage

** Brokerage estimates company's revenue to reach $1 bln by 2032, with each additional $500 bln in sales potentially adding $20 to the stock price

** Kymera's shares rose 58.7% in 2024

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2519393418?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-13 20:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2519393418","market":"us","top_or_hot":-1,"title":"BUZZ-Citigroup starts coverage of Kymera with $52 PT","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Citigroup starts coverage of Kymera with $52 PT</title></head><body><p>** Citigroup starts coverage of Kymera <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' <span>KYMR.O</span> shares with \"buy/high risk\" rating and $52 PT, a ~48% upside to stock's last close</p><p>** Brokerage says company's targeted protein degradation technology offers \"first-in-class\" approaches in the treatment of various inflammatory and immunological diseases</p><p>** Company's atopic dermatitis drug KT-621 has shown \"robust preclinical data\" with potential to achieve \"comparable or superior efficacy\" to Regeneron <span>REGN.O</span> and <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a>'s <span>SASY.PA</span>  Dupixent, Citigroup says</p><p>** Kymera's inflammatory skin disease drug KT-474 has shown promising data in clinical trials, particularly in hidradenitis suppurativa, where it demonstrated a \"remarkable ~60% reduction in symptoms\", positioning it as a potential \"best-in-class\" therapy - brokerage</p><p>** Brokerage estimates company's revenue to reach $1 bln by 2032, with each additional $500 bln in sales potentially adding $20 to the stock price</p><p>** Kymera's shares rose 58.7% in 2024</p><p> (Reporting by Kamal Choudhury in Bengaluru)</p><p> ((Kamal.Choudhury@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Citigroup starts coverage of Kymera with $52 PT</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Citigroup starts coverage of Kymera with $52 PT\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-03-13 20:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Citigroup starts coverage of Kymera with $52 PT</title></head><body><p>** Citigroup starts coverage of Kymera <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' <span>KYMR.O</span> shares with \"buy/high risk\" rating and $52 PT, a ~48% upside to stock's last close</p><p>** Brokerage says company's targeted protein degradation technology offers \"first-in-class\" approaches in the treatment of various inflammatory and immunological diseases</p><p>** Company's atopic dermatitis drug KT-621 has shown \"robust preclinical data\" with potential to achieve \"comparable or superior efficacy\" to Regeneron <span>REGN.O</span> and <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a>'s <span>SASY.PA</span>  Dupixent, Citigroup says</p><p>** Kymera's inflammatory skin disease drug KT-474 has shown promising data in clinical trials, particularly in hidradenitis suppurativa, where it demonstrated a \"remarkable ~60% reduction in symptoms\", positioning it as a potential \"best-in-class\" therapy - brokerage</p><p>** Brokerage estimates company's revenue to reach $1 bln by 2032, with each additional $500 bln in sales potentially adding $20 to the stock price</p><p>** Kymera's shares rose 58.7% in 2024</p><p> (Reporting by Kamal Choudhury in Bengaluru)</p><p> ((Kamal.Choudhury@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2089984988.USD","symbol_name":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250313:nL4N3PW0YV:1","article_id":"2519393418","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2519393418","pubTimestamp":1741869647,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Citigroup starts coverage of Kymera with $52 PT** Citigroup starts coverage of Kymera Therapeutics' KYMR.O shares with \"buy/high risk\" rating and $52 PT, a ~48% upside to stock's last close** Brokerage says company's targeted protein degradation technology offers \"first-in-class\" approaches in the treatment of various inflammatory and immunological diseases** Company's atopic dermatitis drug KT-621 has shown \"robust preclinical data\" with potential to achieve \"comparable or superior efficacy\" to Regeneron REGN.O and Sanofi's SASY.PA  Dupixent, Citigroup says** Kymera's inflammatory skin disease drug KT-474 has shown promising data in clinical trials, particularly in hidradenitis suppurativa, where it demonstrated a \"remarkable ~60% reduction in symptoms\", positioning it as a potential \"best-in-class\" therapy - brokerage** Brokerage estimates company's revenue to reach $1 bln by 2032, with each additional $500 bln in sales potentially adding $20 to the stock price** Kymera's shares","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","KYMR":"Kymera Therapeutics, Inc.","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","BK4585":"ETF&股票定投概念","BK4139":"生物科技","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0882574055.USD":"富达全球健康医疗A ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","REGN":"再生元制药公司","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","LU0058720904.USD":"联博国际健康护理基金A","LU0053666078.USD":"摩根大通基金-美国股票A（离岸）美元","BK4588":"碎股","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU1917777945.USD":"安联专题基金Cl AT Acc"},"translate_title":"BUZZ-花旗集团开始以52美元PT的价格覆盖Kymera","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"REGN":0.9,"KYMR":0.9},"content_text":"BUZZ-Citigroup starts coverage of Kymera with $52 PT** Citigroup starts coverage of Kymera Therapeutics' KYMR.O shares with \"buy/high risk\" rating and $52 PT, a ~48% upside to stock's last close** Brokerage says company's targeted protein degradation technology offers \"first-in-class\" approaches in the treatment of various inflammatory and immunological diseases** Company's atopic dermatitis drug KT-621 has shown \"robust preclinical data\" with potential to achieve \"comparable or superior efficacy\" to Regeneron REGN.O and Sanofi's SASY.PA  Dupixent, Citigroup says** Kymera's inflammatory skin disease drug KT-474 has shown promising data in clinical trials, particularly in hidradenitis suppurativa, where it demonstrated a \"remarkable ~60% reduction in symptoms\", positioning it as a potential \"best-in-class\" therapy - brokerage** Brokerage estimates company's revenue to reach $1 bln by 2032, with each additional $500 bln in sales potentially adding $20 to the stock price** Kymera's shares rose 58.7% in 2024 (Reporting by Kamal Choudhury in Bengaluru) ((Kamal.Choudhury@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2519393418","isCrawlerRequest":true}